T. Rowe Price Associates, Inc. Acquires 5.5% Stake in MediWound Ltd (MDWD)

On May 15, 2026, T. Rowe Price Associates, Inc. filed a Schedule 13G with the SEC, reporting a new 5.5% stake in MediWound Ltd (MDWD). As of the event date on March 31, 2026, the investment firm beneficially owns 709,847 shares of the issuer's common stock. The filing indicates that T. Rowe Price Associates holds sole dispositive power over all 709,847 shares and sole voting power over 707,170 shares. This position represents a significant increase from zero shares previously held, establishing the firm as a major institutional shareholder. The securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the company. The filing was signed by Ellen York, Vice President of T. Rowe Price Associates, Inc., confirming the passive nature of the investment. MediWound Ltd is an Israel-based biopharmaceutical company focused on tissue regeneration and wound care.